Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling.
Journal: Biomolecules
Published: August 06, 2025
Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis.
Journal: Cancers
Published: January 01, 2025
Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.
Journal: Cancers
Published: December 30, 2023
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.
Journal: Breast cancer research and treatment
Published: February 22, 2023
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Journal: Cancer research
Published: February 28, 2022
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Journal: Breast cancer research : BCR
Published: November 07, 2021
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Journal: Neuro-oncology advances
Published: September 06, 2021
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 30, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Journal: Communications biology
Published: February 19, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Journal: Cell death discovery
Published: January 07, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026